This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 8 EPO patents. Top assignees: Glaxosmithkline LLC, Glaxosmithkline Intellectual Property Development Limited, Glaxosmithkline Intellectual Property (No.2) Limited. Active years: 2013-2025.
Company Filing History:
8 out of 358 
4 out of 240 
2 out of 95 
Years Active: 2013-2025
Title: The Innovative Contributions of Stuart Paul Romeril
Introduction
Stuart Paul Romeril is a notable inventor based in Collegeville, PA (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, Romeril has made strides in developing innovative compounds that target critical health issues.
Latest Patents
Among his latest patents, Romeril has focused on substituted pyridines as DNA methyltransferase 1 (DNMT1) inhibitors. This invention relates to substituted pyridine derivatives that inhibit the activity of DNMT1. The invention also encompasses pharmaceutical compositions that include these compounds and methods for using them in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases linked to inappropriate DNMT1 activity.
Career Highlights
Throughout his career, Romeril has worked with prominent companies such as GlaxoSmithKline LLC and GlaxoSmithKline Intellectual Property Development Limited. His work in these organizations has allowed him to contribute to the advancement of medical science and therapeutic solutions.
Collaborations
Romeril has collaborated with esteemed colleagues, including William Henry Miller and Neil W Johnson. These partnerships have further enriched his research and development efforts.
Conclusion
Stuart Paul Romeril's innovative work in the pharmaceutical industry, particularly in developing DNMT1 inhibitors, showcases his commitment to addressing significant health challenges. His contributions continue to impact the field positively.